insights_auto
Why is CRSP up 5,85%?
Dive Deeperchevron_right
CRSP:NASDAQ
Crispr Therapeutics AG
53,39 $
arrow_upward
+5,85%(+2,95) 1D
54,10 $
arrow_upward
+1,33% (+0,71)bedtimeAfter hours
Closed: 9 қаз., 16:00:00 GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for CRSP...
Open
50,82 $
High
54,07 $
Low
50,52 $
Mkt. cap
5,16 млрд
Avg. vol.
1,62 млн
Volume
1,47 млн
52-wk high
78,00 $
52-wk low
44,12 $
EPS
-4,76 $
Beta
1,45
Shares outstanding
96,69 млн
No. of employees
393
Open
50,82 $
High
54,07 $
Low
50,52 $
Mkt. cap
5,16 млрд
Avg. vol.
1,62 млн
Volume
1,47 млн
52-wk high
78,00 $
52-wk low
44,12 $
EPS
-4,76 $
Beta
1,45
Shares outstanding
96,69 млн
No. of employees
393
News stories
From web sources and news partners
Simply Wall Street
·
10 сағат бұрын
Upcoming CTX310 Data Could Test The Case For CRISPR Therapeutics Stock
Investing.com
·
10 сағат бұрын
Cathie Wood’s ARK sells DraftKings stock and buys CRISPR Therapeutics
MarketBeat
·
18 сағат бұрын
CRISPR Therapeutics (NASDAQ:CRSP) Shares Climb 5.7% - What's Next?
The Motley Fool
·
20 сағат бұрын
Citi Sees 60% Upside in CRISPR Therapeutics. Here's What Has to Go Right.
Profile
CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. The company does business as CRISPR Therapeutics, Inc. in the United States. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland; Boston, Massachusetts; San Francisco, California; and London, United Kingdom. Its manufacturing facility in Framingham, Massachusetts, won the Facilities of the Year Award award in 2022. The company’s lead program, exagamglogene autotemcel, or exa-cel, was granted regulatory approval by the US Food and Drug Administration in December 2023. Wikipedia
About Crispr Therapeutics AG